Unknown

Dataset Information

0

Mechanistic insight of predictive biomarkers for antitumor PD?1/PD?L1 blockade: A paradigm shift towards immunome evaluation (Review).

ABSTRACT: Checkpoint inhibitor?based immunotherapy has exhibited unprecedented success in the treatment of advanced?stage cancer in recent years. Several therapeutic antibodies targeting programmed death?1 (PD?1) or its ligand (PD?L1) have received regulatory approvals for the treatment of multiple malignancies, including melanoma, non?small cell lung cancer, kidney cancer and Hodgkin's lymphoma. However, a substantial proportion of patients still do not benefit from these agents, let alone the risk of immune?associated toxicities and financial burden. Therefore, it is imperative to identify valid predictive biomarkers which can help optimize the selection of patients. In this review, a mechanism?based interpretation of tumor PD?L1 expression and other candidate biomarkers of response to antitumor PD?1/PD?L1 blockade was provided, particularly for the tumor microenvironment?derived 'immunomes', and the challenges faced in their clinical use was addressed. Directions for future biomarker development and the potential of combined biomarker strategies were also proposed.

SUBMITTER: You W 

PROVIDER: S-EPMC7336519 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Mechanistic insight of predictive biomarkers for antitumor PD‑1/PD‑L1 blockade: A paradigm shift towards immunome evaluation (Review).

You Wenjie W   Shang Bin B   Sun Jian J   Liu Xueqing X   Su Lili L   Jiang Shujuan S  

Oncology reports 20200611 2

Checkpoint inhibitor‑based immunotherapy has exhibited unprecedented success in the treatment of advanced‑stage cancer in recent years. Several therapeutic antibodies targeting programmed death‑1 (PD‑1) or its ligand (PD‑L1) have received regulatory approvals for the treatment of multiple malignancies, including melanoma, non‑small cell lung cancer, kidney cancer and Hodgkin's lymphoma. However, a substantial proportion of patients still do not benefit from these agents, let alone the risk of im  ...[more]

Similar Datasets

Unknown Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives.
| S-EPMC7450549 | biostudies-literature
Unknown PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
| S-EPMC5723106 | biostudies-literature
Unknown PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine Immunization.
| S-EPMC4527948 | biostudies-literature
Unknown Microwave ablation combined with PD-L1 blockade synergistically promotes Cxcl9-mediated antitumor immunity.
| S-EPMC11247550 | biostudies-literature
Unknown PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors.
| S-EPMC5241182 | biostudies-literature
Unknown Pirfenidone facilitates immune infiltration and enhances the antitumor efficacy of PD-L1 blockade in mice.
| S-EPMC7781712 | biostudies-literature
Unknown CD73 and PD-L1 dual blockade amplifies antitumor efficacy of SBRT in murine PDAC models.
| S-EPMC10163599 | biostudies-literature
Unknown Targeting IFN? to tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockade resistance.
| S-EPMC6214895 | biostudies-other
Unknown Molecular insight into binding affinities and blockade effects of selected flavonoid compounds on the PD-1/PD-L1 pathway.
| S-EPMC11328830 | biostudies-literature
Unknown PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy.
| S-EPMC7460585 | biostudies-literature